Glaucoma

A new therapy provides noninvasive nighttime IOP control by programming the desired pressure into the device, explained John Berdahl, MD, during the New Horizons Forum.

Glaukos Corporation's COO Chris Calcaterra gives an update on the company's latest 24-month phase 2b data for its iDose TR sustained-release travoprost implant, next steps for securing FDA approval, and his outlook for 2021.

Oluwatosin U. Smith, MD, Glaucoma Associates of Texas, provides an update on optimization and surgical modifications of newer glaucoma surgeries.

Joseph F. Panarelli, MD, associate professor of ophthalmology, NYU Langone Medical Center, shares some clinical pearls for managing masquerade syndromes and determining when it is not glaucoma.

Donald L. Budenz, MD, MPH, shares the key takeaways from his Shaffer-Hetherington-Hoskins Lecture, focusing on glaucoma epidemiology, presented during the 2021 Glaucoma 360's 25th Annual Glaucoma Symposium CME.

Noninvasive option reduces IOP in patients with glaucoma.

The traditional treatment for primary angle-closure (PAC) and PAC glaucoma (PACG) is laser peripheral iridotomy (LPI) to facilitate aqueous outflow followed by medical treatment with drops to decrease the intraocular pressure (IOP).

Sunita Radhakrishnan, MD, in a presentation at the 25th annual Glaucoma Symposium at the Glaucoma 360 virtual annual event, noted that concomitant treatment of both glaucoma and dry eye is key.

Robert L. Stamper, MD, discusses the findings of a study analyzing the effects of corneal mechanics on IOP, presented during the virtual Glaucoma 360 meeting.

During the 2021 Glaucoma 360 meeting, Ruth D. Williams, MD, speaks on the highlights and key findings from the EAGLE study, which showed clear lens extraction surgery may be a better initial treatment for some glaucoma patients.

Amid a pandemic, the Glaucoma Research Foundation is holding its annual gala online, funding aspirations for a glaucoma-free world with a goal of raising $1 million.

Two teams of researchers from Gyroscope Therapeutics and the University of Pennsylvania are joining forces to explore gene therapy targets for three specific serious eye diseases.

New options open possibilities for treatment, resulting in better outcomes for patients.

In light of an unprecedented year filled with technological advancements and pivots, Joshua Mali, MD, offers his top 5 predictions in ophthalmology for 2021.

Tanner Ferguson, MD, Cole Eye Institute, discusses findings from the study "Trabecular Micro-bypass Stent Implantation (iStent)" + Phacoemulsification in PXG: Six-Year Outcomes," during the virtual AAO 2020 meeting.

In light of the ongoing COVID-19 pandemic, the Glaucoma Research Foundation will host a virtual Glaucoma 360 annual meeting in 2021.

Michael R. Robinson, MD, shares the highlights of the study "Single administration of intracameral bimatoprost implant 10 µg: IOP lowering and safety," presented during the virtual AAO 2020 meeting.

Davinder Grover, MD, MPH, speaks on the highlights of his presentation regarding outcomes of a 12-year study comparing ab externo vs ab interno xen gel stents in tertiary glaucoma practice.

Goniotomy-viscodilation cataract surgery controls IOP without medications.

Innovation, change has dominated the glaucoma specialty over the years.

Programs use detection and treatment to ease burden of eye disease.

Pharmaceutical representatives share what keeps them up at night within the ophthalmic space.

In this fourth installment on "2020 vision," pharmaceutical representatives share their outlook on what lies ahead for glaucoma innovations within the ophthalmic space.

Glaucoma Research Foundation (GRF) Ambassadors webinar provides platform for idea-sharing by ophthalmologists

Evidence-based medicine can lead to personalized care, better results for patients

One ophthalmic practice's staff has found that, despite the challenges faced by all healthcare professionals amid the coronavirus pandemic, a few proverbial “silver lining” practice adaptations will endure long after the crisis is over.

Options can reduce the treatment burden for patients, leading to improved outcomes

Investigators note the need for less medication over 12-month period

How gonioscopy can offer ophthalmologists an option in treating patients with glaucoma

Researchers must weigh emotional, financial, and reputational considerations